Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 2',3'-Dideoxy‑3'‑fluoro‑uridine‑5'‑diphosphate (FUDP) is a synthetic nucleoside diphosphate analog of uridine. It is characterized by the absence of hydroxyl groups at the 2' and 3' positions and a fluorine substitution at the 3' position on the ribose ring. This compound belongs to the class of organic pyrophosphates and nucleoside analogs[1][4]. As an experimental small molecule with no current clinical approval or known therapeutic indication[3], it is primarily used in biochemical research as a substrate or inhibitor in studies involving nucleotide metabolism and polymerase activity. Its mechanism of action likely involves interference with nucleic acid synthesis due to its structural similarity to natural uridine diphosphates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',3'-dideoxy-3'-fluoro-urididine-5'-diphosphate.